Context Therapeutics Inc
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more
Context Therapeutics Inc (CNTX) - Total Assets
Latest total assets as of September 2025: $79.23 Million USD
Based on the latest financial reports, Context Therapeutics Inc (CNTX) holds total assets worth $79.23 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Context Therapeutics Inc - Total Assets Trend (2016–2024)
This chart illustrates how Context Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Context Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Context Therapeutics Inc's total assets of $79.23 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Context Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Context Therapeutics Inc's current assets represent 99.8% of total assets in 2024, an increase from 71.1% in 2016.
- Cash Position: Cash and equivalents constituted 96.2% of total assets in 2024, up from 67.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 33.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Context Therapeutics Inc Competitors by Total Assets
Key competitors of Context Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Context Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Context Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Context Therapeutics Inc is currently not profitable relative to its asset base.
Context Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.07 | 36.91 | 0.03 |
| Quick Ratio | 13.07 | 36.91 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $72.82 Million | $ 83.74 Million | $ -9.25 Million |
Context Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Context Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.98 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 510.9% |
| Total Assets | $98.13 Million |
| Market Capitalization | $122.17 Million USD |
Valuation Analysis
Above Book Valuation: The market values Context Therapeutics Inc's assets above their book value (1.25 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Context Therapeutics Inc's assets grew by 510.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Context Therapeutics Inc (2016–2024)
The table below shows the annual total assets of Context Therapeutics Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $98.13 Million | +510.90% |
| 2023-12-31 | $16.06 Million | -57.69% |
| 2022-12-31 | $37.97 Million | -26.00% |
| 2021-12-31 | $51.31 Million | +10878.25% |
| 2020-12-31 | $467.34K | +70.84% |
| 2019-12-31 | $273.55K | -99.60% |
| 2017-12-31 | $68.34 Million | +184.67% |
| 2016-12-31 | $24.01 Million | -- |